BioCentury
ARTICLE | Clinical News

MediciNova's ibudilast misses in Phase II for methamphetamine dependence

March 30, 2018 3:16 PM UTC

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported on March 29 that ibudilast (MN-166) missed the primary endpoint of improving methamphetamine abstinence compared with placebo in a Phase II trial to treat methamphetamine dependence.

The trial enrolled about 140 patients seeking treatment for methamphetamine dependence to receive once-daily 100 mg ibudilast or placebo for 12 weeks. Methamphetamine abstinence was confirmed via urine drug screens during the last two weeks of treatment. The University of California Los Angeles sponsored the trial in collaboration with NIH's National Institute on Drug Abuse (NIDA)...